Dermata Therapeutics, Inc. (DRMA)
DRMANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.7700
+0.0060 (+0.79%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.82m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6032 to $4.66
- Average volume
- 3.51m
- Previous close
- $0.7640
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $4.00, +419.5% from here
Earnings
Next report Nov 13, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.76m | -$1.90m | -$1.93m | -$3.01m |
| Net income | -$1.69m | -$1.86m | -$1.85m | -$2.97m |
News
6 latest- Dermata Therapeutics, Inc. Announces Enrollment of First Participant in Tome Clearing Treatment Clinical TrialFintel · Nov 2, 2026
- Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus RTTNews · Sep 8, 2026
- Dermata Therapeutics Reports Q2 2026 Results Ahead Of First Product Launch; Stock Up RTTNews · Aug 12, 2026
- Dermata Therapeutics Announces A Private Placement Valued At Up To $12.4 Mln RTTNews · Dec 26, 2025
- Dermata Therapeutics To Launch First OTC Acne Kit In Mid-2026 RTTNews · Dec 8, 2025
- Dermata Posts Narrower Loss in Q2The Motley Fool · Aug 13, 2025
The company
Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of both direct-to-consumer and professional skincare solutions. The Company leverages its experience in clinical dermatology and its Bioneedle technology to develop differentiated skincare products designed to address a variety of consumer skincare needs. Dermata's first commercial product, Tome Foundational Treatment, is now available at Tome, with additional innovations planned to follow. Dermata is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- dermatarx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.